Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
3.330
-0.020 (-0.60%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Revenue
In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K, down -39.91%. Can-Fite BioPharma had revenue of $203.00K in the half year ending December 31, 2025, a decrease of -42.17%.
Revenue (ttm)
$405.00K
Revenue Growth
-39.91%
P/S Ratio
19.02
Revenue / Employee
$81,000
Employees
5
Market Cap
7.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
| Dec 31, 2015 | 162.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Traws Pharma | 2.73M |
| AIM ImmunoTech | 95.00K |
| Azitra | 7.50K |
| Creative Medical Technology Holdings | 3.00K |
| Soligenix | 2.34K |
| Ernexa Therapeutics | 1,000.00 |
CANF News
- 4 days ago - Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer - GlobeNewsWire
- 9 days ago - Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - GlobeNewsWire
- 18 days ago - Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu - TheFly
- 18 days ago - Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome - GlobeNewsWire
- 4 weeks ago - Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewsWire
- 5 weeks ago - Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment - GuruFocus
- 5 weeks ago - Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson - TheFly
- 5 weeks ago - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - GlobeNewsWire